Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 6—June 2016

Antibody Response and Disease Severity in Healthcare Worker MERS Survivors

Abeer N. AlshukairiComments to Author , Imran Khalid, Waleed A. Ahmed, Ashraf M. Dada, Daniyah T. Bayumi, Laut S. Malic, Sahar Althawadi, Kim Ignacio, Hanadi S. Alsalmi, Hail M. Al-Abdely, Ghassan Y. Wali, Ismael A. Qushmaq, Basem M. Alraddadi, and Stanley Perlman
Author affiliations: King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia (A.N. Alshukairi, I. Khalid, W.A. Ahmed, A.M. Dada, D.T. Bayumi, L.S. Malic, H.S. Alsalmi, G.Y. Wali, I.A. Qushmaq, B.M. Alraddadi); King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia (S. Althawadi, K. Ignacio); General Directorate of Infection Prevention and Control, Ministry of Health, Riyadh (H.M. Al-Abdely); University of Iowa Department of Microbiology, Iowa City, Iowa, USA (S. Perlman)

Main Article


Antibody response in 9 confirmed survivors of MERS-CoV infection, by selected demographic and clinical characteristics, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia, 2014*

Patient no.
Age, y/sex
Clinical presentation
Test results

Serology at 3 mo

Serology at 10 mo

Serology at 18 mo
1 49/M Severe pneumonia 28 26 + (3.17) + + (2.99) + + (3.3) +
2 33/F Severe pneumonia 31 26 + (2.7) + + (2.09) + + (2.9) +
3 54/F Pneumonia 34 ND + (2.91) + + (1.9) + ND ND
4 40/M Pneumonia 32 ND + (1.29) + – (0.65) ND ND
5 37/M Pneumonia 35 ND + (3.2) + + (1.2) ND ND
6 36/M URTI 32 ND – (0.07) – (0.07) ND ND
7 27/F Asymptomatic 33 ND – (0.046) – (0.04) ND ND
8 28/F Asymptomatic 32 ND – (0.12) – (0.06) ND ND
9 35/M Asymptomatic 33 ND – (0.07) – (0.04) ND ND

*+, positive; –, negative; BAL, broncholaveolar lavage; Ct, cycle threshold; IFA, indirect-immunofluorescence assay; MERS-CoV, Middle East respiratory syndrome coronavirus; ND, not done; NPS, nasopharyngeal swab; URTI, upper respiratory tract infection.
†ELISA for MERS-CoV S gene antibody; positive defined as a value >1.1, negative as <0.8, and borderline as between 0.8 and 1.1.
‡IFA for MERS-CoV IgG; endpoint titers not done.

Main Article

Page created: May 16, 2016
Page updated: May 16, 2016
Page reviewed: May 16, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.